Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. [PDF]
Albash R +3 more
europepmc +1 more source
Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. [PDF]
Albash R +3 more
europepmc +1 more source
Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. [PDF]
Redon J, Weber MA, Reimitz PE, Wang JG.
europepmc +1 more source
Small bowel enteropathy associated with olmesartan medoxomil treatment. [PDF]
Galanopoulos M +7 more
europepmc +1 more source
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. [PDF]
Bakris GL +6 more
europepmc +1 more source
Linear mixed-effects model of QTc prolongation for olmesartan medoxomil. [PDF]
Song S, Matsushima N, Lee J, Mendell J.
europepmc +1 more source
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. [PDF]
Neutel JM +4 more
europepmc +1 more source

